Percutaneous transluminal coronary angioplasty restenosis after

Moreover, ECP using 8-MOP and UVA radiation has been evaluated during a clinical trial to analyze its efficacy for the treatment of clinical restenosis after percutaneous transluminal coronary angioplasty [260]. After this study, ECP has been shown to be effective in reducing restenosis in patients undergoing balloon percutaneous transluminal coronary angioplasty with and without stent deployment. However, the use of this procedure in this com-phcation needs further investigations. 

Cairns JA, Gill J, Morton B, Roberts R, Gent M, Hirsh J, Holder D, Finnie K, Marquis JF, Naqvi S, Cohen E. Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study. Circulation 1996 94(7) 1553-60. 

Schwartz L, Bourassa MG, Lesperance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988 318 1714-1719. 

Yokoi H, Daida H, Kuwabara Y et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997 30 855-862. 

Mulder HJ, Bal ET, Jukema JW, et al. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial). Am J Cardiol 2000 86 742-746,... 

In the past, several clinical studies with corticosteroids failed to demonstrate a significant reduction in coronary restenosis after percutaneous transluminal coronary angioplasty (35,36). However, as we mentioned previously, after balloon angioplasty, there were other mechanisms involved in the pathophysiology of coronary restenosis (such as acute wall recoil or chronic remodeling) that explained the negative results of those studies (35,36). 

Rodriguez A, Santaera O, Larribau M, Sosa Ml, Palacios IF Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosis. AmJ Cardiol 1993 71 1391-1395. 

MacDonald RG, Panush RS, Pepine CJ, Rationale for use of glucocorticoids in modification of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1987 60 B56-B60. 

Corcos T, David PR, Val PG, et al. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1985 109(5 Fft I ) 926-93 I. 

Okamoto S, Inden M, Setsuda M, Konishi T, Nakano T Effects oftrapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1992 123(6) 1439-1444. 

Serruys FW, Rutsch W Heyndrickx GR, et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT). Circulation 1991 84(4) 1568-1580. 

Knudtson ML, FlintoftVp Roth DL, Hansen JL, DuffHJ. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1990 l5(3) 69l-697. 

Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty Results of the MERCATOR study a multicenter, randomized, double-blind placebo-controlled trial, Circulation 1992 86(1) 100-1 10. 

Nye ER, Ablett MB, Robertson MC, llsley CD, Sutherland WH. Effect of eicosapentaenoic acid on restenosis rate, clinical course and blood lipids in patients after percutaneous transluminal coronary angioplasty, Aust N ZJ Med 1990 20(4) 549-552. 

Hokimoto S, Oike T Saito T et al. Increased expression of monocyte chemoattractant protein-1 in atherectomy specimens from patients with restenosis after percutaneous transluminal coronary angioplasty. CircJ 2002 66 1 14-1 16. 

Hohnes DR Jr, Vhetstra RE, Smith HC, Vetrovec, GW, Kent KM, Cowley HJ, Faxon DP, Gruentzig AR, Kelsey SF, Detre KM. Restenosis after percutaneous transluminal coronary angioplasty (PTCA) a report from the PTCA Registry of the National Heart, Lung and Blood Institute. Am J Cardiol 1984 53 77C-81C. 

Milner, M.R., Galhno, R.A., LeffingweU, A., Pichard, A.D., Brooks-Robinson, S., Rosenberg, J., Little, T., and Lindsay, J. (1989) Usefulness of Fish Oil Supplements in Preventing Clinical Evidence of Restenosis After Percutaneous Transluminal Coronary Angioplasty, Am. J. Cardiol. 64,294-299. 

Slack, J.D., Pinkerton, C.A., VanTassel, J., Orr, C.M., and Nasser, W.K. (1987) Can Oral Fish Oil Supplement Minimize Restenosis After Percutaneous Transluminal Coronary Angioplasty J. Am. Coll. Cardiol. 9, 64A (Abstr.). 

Cairns, J.A., GUI,J., Morton, B.,Roberts, R., Gent,M., Hhsh, J., Holder, D., Finnie, K., Marquis, J.F., Naqvi, S., and Cohen, E. (1996) Fish Oils and Low-Molecular-Weight Heparin for the Reduction of Restenosis After Percutaneous Transluminal Coronary Angioplasty. The EMPAR Study, Circulation 94, 1553-1560. 

Nobuyoshi, M., Kimura, T., Nosaka, H., Mioka, S., Ueno, K., Yokoi, H., Hamasaki, N., Horiuchi. H.. and Ohishi, H. (1988) Restenosis After Successful Percutaneous Transluminal Coronary Angioplasty Serial Angiographic Follow-Up of 229 Patients, J. Am. Coll. Cardiol. 12,61 623. 

Matsuura R, Isaka N, Imanaka-Yoshida K, Yoshida T, Sakakura T and Nakano T. Deposition of PG-M/versican is a major cause of human coronary restenosis after percutaneous transluminal coronary angioplasty. J Pathol 180 311-6, 1996. 

Waksman R, Kosinski AS, Klein L, et al. Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. Lovastatin Restenosis Trial Group, Am J Cardiol 1996 78 221-224. 

---